TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients  by Jariwala, Neha et al.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at www.jidonline.org, and at
http://dx.doi.org/10.1016/j.jid.2016.07.032.
This work is licensed under
a Creative Commons Attri-
bution-NonCommercial-NoDeriva-
tives 4.0 International License. To view
a copy of this license, visit http://
creativecommons.org/licenses/by-nc-
nd/4.0/
N Jariwala et al.
Elevated Helios and TIGIT in Se´zary SyndromeJared Malke1, Lauren E. Haydu1,
John D. Reveille8, Dawen Sui9,
Roland L. Bassett, Jr9, Nadya Koshkina10,
Marie Franc¸oise Avril11, Mason Lu1,
Qingyi Wei12, Florence Demenais2,3,15,
Christopher I. Amos13,15
and Jeffrey E. Lee1,15,*
1Department of Surgical Oncology, The
University of Texas MD Anderson Cancer
Center, Houston, Texas, USA; 2INSERM,
Genetic Variation and Human Diseases Unit,
Paris, France; 3Universite´ Paris Diderot,
Sorbonne Paris Cite´, Institut Universitaire
d’He´matologie, Paris, France; 4Department of
Cancer Biology, The University of Texas MD
Anderson Cancer Center, Houston, Texas,
USA; 5The Fifth Affiliated Hospital of
Zhengzhou University, Zhengzhou, Henan,
China; 6Department of Pathology, The
University of Texas MD Anderson Cancer
Center, Houston, Texas, USA; 7Department of
Clinical Applications and Support, The
University of Texas MD Anderson Cancer
Center, Houston, Texas, USA; 8Division of
Rheumatology and Clinical Immunogenetics,
The University of Texas Health Science Center,
Houston, Texas, USA; 9Department of
Biostatistics, The University of Texas MD
Anderson Cancer Center, Houston, Texas,
USA; 10Department of Head and Neck Surgery,
The University of Texas MD Anderson Cancer
Center, Houston, Texas, USA; 11AP-HP,
Hoˆpital Cochin et Universite´ Paris Descartes,
Paris, France; 12Duke Cancer Institute, Duke
University Medical Center and Department of
Medicine, Duke University School of
Medicine, Durham, North Carolina, USA; andAbbreviations: HD, healthy donor; MF, mycosis fung
Syndrome; Th, T helper; TIGIT, T-cell immunorecept
Accepted manuscript published online 1 September 2
2016
ª 2016 The Authors. Published by Elsevier, Inc. on b
This is an open access article under the CC BY-NC-N
nc-nd/4.0/).13Department of Community and Family
Medicine, Geisel College of Medicine,
Dartmouth College, Lebanon, New
Hampshire, USA
14These authors contributed equally to this work.
15These authors contributed equally to this work.
*Corresponding authors e-mail: sfang@
mdanderson.org or jelee@mdanderson.orgREFERENCES
Amos CI, Wang LE, Lee JE, Gershenwald JE,
Chen WV, Fang S, et al. Genome-wide associ-
ation study identifies novel loci predisposing to
cutaneous melanoma. Hum Mol Genet
2011;20:5012e23.
Brossard M, Fang S, Vaysse A, Wei Q, Chen WV,
Mohamdi H, et al. Integrated pathway and
epistasis analysis reveals interactive effect of
genetic variants at TERF1 and AFAP1L2 loci on
melanoma risk. Int J Cancer 2015;137:
1901e9.
Chaudru V, Chompret A, Bressac-De Paillerets B,
Spatz A, Avril MF, Demenais F. Influence of
genes, nevi, and sun sensitivity on melanoma
risk in a family sample unselected by family
history and in melanoma-prone families. J Natl
Cancer Inst 2004;96:785e95.
Conway C, Beswick S, Elliott F, Chang YM, Ran-
derson-Moor J, Harland M, et al. Deletion at
chromosome arm 9p in relation to BRAF/NRAS
mutations and prognostic significance foroides; SD, standard deviation; SS, Se´zary
or with Ig and ITIM domains
016; corrected proof published online 20 October
ehalf of the Society for Investigative Dermatology.
D license (http://creativecommons.org/licenses/by-primary melanoma. Genes Chromosomes
Cancer 2010;49:425e38.
Geller AC, Mayer JE, Sober AJ, Miller DR,
Argenziano G, Johnson TM, et al. Total nevi,
atypical nevi, and melanoma thickness: an
analysis of 566 patients at 2 US centers. JAMA
Dermatol 2016;152:413e8.
Li J, Martinka M, Li G. Role of ING4 in human
melanoma cell migration, invasion and patient
survival. Carcinogenesis 2008;29:1373e9.
Liu JZ, Mcrae AF, Nyholt DR, Medland SE,
Wray NR, Brown KM, et al. A versatile gene-
based test for genome-wide association
studies. Am J Hum Genet 2010;87:139e45.
Rangel J, Nosrati M, Leong SP, Haqq C,
Miller JR III, Sagebiel RW, et al. Novel role for
RGS1 in melanoma progression. Am J Surg
Pathol 2008;32:1207e12.
Santonocito C, Capizzi R, Concolino P,
Lavieri MM, Paradisi A, Gentileschi S, et al.
Association between cutaneous melanoma,
Breslow thickness and vitamin D receptor BsmI
polymorphism. Br J Dermatol 2007;156:
277e82.
Winnepenninckx V, Lazar V, Michiels S, Dessen P,
Stas M, Alonso SR, et al. Gene expression
profiling of primary cutaneous melanoma and
clinical outcome. J Natl Cancer Inst 2006;98:
472e82.TIGIT and Helios Are Highly Expressed on
CD4D T Cells in Se´zary Syndrome Patients
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Cutaneous T-cell lymphoma is
commonly manifested as skin-restricted
mycosis fungoides (MF) or Se´zary syn-
drome (SS), a leukemic variant charac-
terized by erythroderma and circulating
malignant CD4D T cells with features
of T helper T(h) type 2 cells (Kim et al.,
2005).
T-cell immunoreceptor with Ig and
ITIM domains (TIGIT) is a recentlyidentified co-inhibitory receptor
expressed on the cell surface of acti-
vated or regulatory T cells and natural
killer cells. Emerging data suggest that
TIGIT plays an inhibitory role by
down-regulating Th1 and Th17 while
enhancing Th2 immune responses
(Johnston et al., 2015; Joller et al.,
2014; Kourepini et al., 2016; Kurtulus
et al., 2015; Zhang et al., 2016). He-
lios is a transcription factor in theIkaros family present in regulatory T
cells. Like TIGIT, Helios has inhibitory
activity and plays a role in antitumor
immunity (Khaitan et al., 2016; Muto
et al., 2015; Sebastian et al., 2016).
The expression and role of Helios and
TIGIT in SS have not been explored,
but given the immunosuppressive
nature of the disease, both molecules
may potentially contribute to this
process.
We reported high expression of
FCRL3 on CD26e CD4DT cells in SS
patients with high blood tumor
burden. A microarray analysis of
global gene expression that identified
FCRL3 also showed significantly
increased expression of Helios in
CD4D cells from SS patients with highwww.jidonline.org 257
Figure 1. Helios, TIGIT, and FCRL3 are highly expressed in skin and peripheral blood mononuclear cells of Se´zary syndrome patients. (a, b) The (a) cell surface
expression of TIGIT and (b) intracellular expression of Helios were assessed by flow cytometry in CD4D T cells from SS patients (n ¼ 25), MF patients (n ¼ 5),
and HDs (n ¼ 5). Results are expressed with the mean. (cee) Skin samples from 11 SS, 7 MF, 4 atopic dermatitis, and 3 psoriasis patients and 8 normal controls
(HDs, pooled samples) were examined for mRNA expression of (c) TIGIT, (d) Helios, and (e) FCRL3 by quantitative real-time reverse transcriptaseePCR. AD,
atopic dermatitis; HD, healthy donor; MF, mycosis fungoides; PS, psoriasis; SS, Se´zary syndrome; TIGIT, T cell immunoreceptor with Ig and ITIM domains.
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(Wysocka et al., 2014). A recent report
linked the expression of FCRL3 with
the expression of TIGIT and Helios
(Bin Dhuban et al., 2015).
Our data show significantly
increased percentages of TIGITD and
HeliosD CD4D T cells in patients with
SS (mean ¼ 33.6%, P ¼ 0.02 and
mean ¼ 35.7%, P ¼ 0.0001, respec-
tively) when compared with patients
with MF and healthy donors (HDs)
(Figure 1a and b). TIGIT and Helios
were also highly expressed in the skin
of SS and MF patients compared with
atopic dermatitis, psoriasis, and control
skin (HD) (Figure 1cee). TIGIT mRNA
in skin from SS and MF patients was
327- and 110-fold increased, respec-
tively, compared with levels in atopic
dermatitis patients or control skin
(Figure 1c). Similarly, Helios mRNAJournal of Investigative Dermatology (2017), Volumwas increased in the skin of SS and MF
patients at 77- and 13.6-fold, respec-
tively (Figure 1d), along with FCRL3 at
765- and 68.3-fold for SS and MF,
respectively, when compared with HD
skin (Figure 1e).
The data presented in Figure 1a
distinguish patients with a high and low
percentages of TIGITD CD4D T cells. A
thorough analysis of patients with high
TIGIT expression (mean ¼ 79.3%,
standard deviation [SD] ¼ 9.7)
(Figure 2a) showed that patients’ CD4D
T cells also show a high percentage of
CD26e cells (mean ¼ 87.1%, SD ¼
9.6), express a single TCRVb (mean ¼
85.9%, SD ¼ 11.3), highly express
Helios (mean ¼ 46.7%, SD ¼ 19.4),
FCRL3 (mean ¼ 64.9% SD ¼ 25.7), and
CD164 (mean ¼ 56.7%, SD ¼ 26.6),
but low PD1 (mean ¼ 22.1%, SD ¼
15.8). Importantly, TIGIT expressione 137correlated positively and significantly
with CD26 negativity and with a single
TCRVb (Figure 2b and c) but not with
the expression of Helios, FCRL3, and
CD164 because of the variability be-
tween patients.
Patients with low expression of
TIGIT on CD4D T cells (mean ¼ 7.9%,
SD ¼ 5.12) (Figure 2d) also show a low
percentage of CD26 negativity
(mean ¼ 28.5%, SD ¼ 18.7), no
detectable single TCRVb, low expres-
sion of Helios (mean ¼ 29.6%, SD ¼
26.1), FCRL3 (mean ¼ 11.9%,
SD ¼ 13.5), CD164 (mean ¼ 21.5%,
SD ¼ 22.7), and PD1 (mean ¼ 10.0%,
SD ¼ 12.6). This group of patients
lacks a well-defined cell surface ma-
lignant phenotype, with the percent-
ages of CD4þ T cells expressing the
aforementioned molecules being
significantly lower compared with
Figure 2. High TIGIT expression correlates with high percentage of single TCRVbDCD4D T cells and loss of CD26 expression and is associated with
impaired cytokine production. (a) Peripheral blood mononuclear cells from patients with high TIGIT expression (n ¼ 9, including 7 patients with defined
TCRVb) were analyzed by flow cytometry to assess the expression of molecules on CD4D T cells. (b, c) High TIGIT expression in CD4D T cells correlates
significantly with (b) high percentage of CD26e (r ¼ 0.75, P ¼ 0.01, n ¼ 9) and (c) single TCRVbþ CD4D T cells (r ¼ 0.81, P ¼ 0.02, n ¼ 7). (d) Flow cytometry
analysis of peripheral blood mononuclear cells from patients with low TIGIT expression to assess the expression of molecules on patients’ CD4D T cells. In
this group of patients, there is a significant decrease in the percentages of CD4D T cells expressing tested molecules compared with the percentages for
corresponding molecules in patients with high TIGIT expression (P < 0.05). (e, f) TIGITDCD4þ T cells from patients with high TIGIT expression produce
significantly less (e) IFN-g (P ¼ 0.001, n ¼ 6) and (f) IL-2 (P ¼ 0.003, n ¼ 6) compared with TIGITe CD4þ T cells from these patients. (g, h) In patients with low
TIGIT expression there were no differences in levels of (g) IFN-g and (h) IL-2 production between TIGITD and TIGITe CD4D T cells (n ¼ 6). TIGIT, T-cell
immunoreceptor with Ig and ITIM domains.
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0.05 for all tested molecules), implying
that low TIGIT-expressing patients
have a low circulating tumor burden.
We analyzed the clinical differences
between the high and low TIGIT/
Helios groups in terms of tumor
burden in the blood, stage, and LDH
and found that all patients in the high-
TIGIT group (n ¼ 9) had a diagnosis of
advanced B2 disease, whereas among
16 patients with low TIGIT expression,
10 (62.5%) patients had diagnoses of
B0 and 6 (37.5%) patients of B1
disease.TIGIT is a known activation marker
and is expressed on chronically acti-
vated, exhausted CD4D T cells (Chew
et al., 2016; Le Mercier et al., 2015;
Pauken and Wherry, 2014). Further-
more, as we show, it is highly expressed
on CD26L TCRVbD CD4D T cells,
defined as the malignant population
in SS. We observed significantly
decreased production of IFN-g and IL-2
by TIGITD compared with TIGITe
CD4D T cells from patients with high
TIGIT expression and advanced B2
disease (Figure 2e and f). This is
consistent with the reported function ofTIGIT-positive, exhausted T cells and is
strongly suggestive that TIGIT is asso-
ciated with an immunosuppressive
phenotype typically observed in
advanced SS by being expressed on both
exhausted and malignant CD4D T cells
(Joller et al., 2014; Kourepini et al.,
2016; Kurtulus et al., 2015). In contrast
to patients with high TIGIT expression,
TIGITD CD4D T cells from patients with
lowTIGITexpressionproduce IFN-g and
IL-2 at levels comparable to their
TIGITecells (Figure 2g and h). These re-
sults suggest that lowTIGITexpression in
these patients may be linked towww.jidonline.org 259
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than to an exhausted phenotype.
The precise pathogenic nature of
cells expressing TIGIT and Helios
molecules in cutaneous T-cell lym-
phoma currently remains unknown.
TIGITD and/or HeliosD CD4D T cells
may represent malignant cells,
exhausted cells, or nonconventional
CD4D T regulatory cells, lacking Foxp3
and CD25 (data not shown). Malignant
Foxp3DCD25e CD4D T cells with
suppressive activity have been identi-
fied in SS patients, further suggesting
that the typical phenotype of T regula-
tory cells may be challenged in the
context of cutaneous T-cell lymphoma
(Heid et al., 2009).
High expression of TIGIT and Helios
identifies CD4D T cells with impaired
immunological functions, primarily
among patients with an advanced stage
of SS, suggesting that high expression of
these molecules may correlate with a
poor prognosis. However, further
studies are needed to define in
detail the functional and biological
significance of TIGIT- and Helios-
expressing CD4D T cells in SS and the
potential use of these markers as ther-
apeutic targets.
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